{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:38:04Z","timestamp":1780475884843,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:00:00Z","timestamp":1480636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shire International GmbH"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.007","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T14:20:56Z","timestamp":1477059656000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Treatment-na\u00efve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials"],"prefix":"10.1016","volume":"68","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derlis E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadhami Ben","family":"Turkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.007_bb0005","series-title":"Williams Hematology","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2015"},{"key":"10.1016\/j.bcmd.2016.10.007_bb0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated\u00ae human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0015","author":"Genzyme Corporation"},{"key":"10.1016\/j.bcmd.2016.10.007_bb0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-\u03b2-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.bcmd.2016.10.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130081","article-title":"Glycosylation and functionality of recombinant \u03b2-glucocerebrosidase from various production systems","volume":"33","author":"Tekoah","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2010.07.008","article-title":"Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease","volume":"46","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","article-title":"Seven-year safety and efficacy with velaglucerase alfa for treatment-na\u00efve adult patients with type 1 Gaucher disease","volume":"90","author":"Zimran","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","article-title":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase","volume":"117","author":"Smith","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0080","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group","volume":"843","author":"WHO Study Group","year":"1994","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0085","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0095","doi-asserted-by":"crossref","first-page":"151506","DOI":"10.1155\/2013\/151506","article-title":"Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience","volume":"2013","author":"Tukan","year":"2013","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0105","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy","volume":"33","author":"Stein","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher registry","volume":"27","author":"Khan","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4\u20135years","volume":"158","author":"Hollak","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4236\/ojgen.2013.31004","article-title":"Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly","volume":"3","author":"Weinreb","year":"2013","journal-title":"Open J. Genet."},{"key":"10.1016\/j.bcmd.2016.10.007_bb0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616301905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616301905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:16Z","timestamp":1761050056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616301905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":25,"alternative-id":["S1079979616301905"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-na\u00efve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Shire Human Genetic Therapies, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}